1. Home
  2. APAM vs VRDN Comparison

APAM vs VRDN Comparison

Compare APAM & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artisan Partners Asset Management Inc.

APAM

Artisan Partners Asset Management Inc.

HOLD

Current Price

$44.37

Market Cap

2.9B

Sector

Finance

ML Signal

HOLD

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

HOLD

Current Price

$33.30

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APAM
VRDN
Founded
1994
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.7B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
APAM
VRDN
Price
$44.37
$33.30
Analyst Decision
Hold
Strong Buy
Analyst Count
3
13
Target Price
$46.00
$41.17
AVG Volume (30 Days)
397.5K
1.4M
Earning Date
02-03-2026
02-26-2026
Dividend Yield
8.19%
N/A
EPS Growth
2.95
N/A
EPS
3.71
N/A
Revenue
$1,158,234,000.00
$70,789,000.00
Revenue This Year
$8.56
$26,257.62
Revenue Next Year
$7.04
$4.54
P/E Ratio
$11.96
N/A
Revenue Growth
8.88
23340.07
52 Week Low
$32.75
$9.90
52 Week High
$48.50
$34.29

Technical Indicators

Market Signals
Indicator
APAM
VRDN
Relative Strength Index (RSI) 61.39 60.22
Support Level $42.27 $29.63
Resistance Level $44.77 $34.29
Average True Range (ATR) 1.02 1.29
MACD 0.25 0.14
Stochastic Oscillator 89.46 81.71

Price Performance

Historical Comparison
APAM
VRDN

About APAM Artisan Partners Asset Management Inc.

Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. In addition to its equity strategies, customers may invest in a fixed-income strategy. Strategies are often distributed to customers ranging from retail investors to institutional investors through specialized channels.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Share on Social Networks: